BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 32157936)

  • 41. Risk adapted therapeutic strategy in newly diagnosed acute myeloid leukemia: Refining the outcomes of ELN 2017 intermediate-risk patients.
    Mohty R; Massoud R; Chakhachiro Z; Mahfouz R; Nassif S; El-Cheikh J; Bazarbachi A; Abou Dalle I
    Leuk Res; 2021 Jun; 105():106568. PubMed ID: 33857784
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Allogeneic hematopoietic stem cell transplantation could improve survival of cytogenetically normal adult acute myeloid leukemia patients with DNMT3A mutations.
    Xu Y; Sun Y; Shen H; Ding L; Yang Z; Qiu H; Sun A; Chen S; Wu D
    Am J Hematol; 2015 Nov; 90(11):992-7. PubMed ID: 26223865
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Long-Term Follow-Up and Impact of Comorbidity before Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Relapsed or Refractory Acute Myeloid Leukemia-Lessons Learned from the Prospective BRIDGE Trial.
    Middeke JM; Herbst R; Parmentier S; Bug G; Hänel M; Stuhler G; Schäfer-Eckart K; Rösler W; Klein S; Bethge W; Bitz U; Büttner B; Knoth H; Alakel N; Schaich M; Morgner A; Kramer M; Sockel K; von Bonin M; Stölzel F; Platzbecker U; Röllig C; Thiede C; Ehninger G; Bornhäuser M; Schetelig J
    Biol Blood Marrow Transplant; 2017 Sep; 23(9):1491-1497. PubMed ID: 28527985
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Efficacy and safety of IAC regimen for relapse/refractory acute myeloid leukemia: a prospective randomized controlled study].
    Li CH; Wei SN; Qiu SW; Gong BF; Gong XY; Li Y; Liu YT; Fang QY; Zhang GJ; Liu KQ; Zhou CL; Lin D; Liu BC; Wang Y; Mi YC; Wei H; Wang JX
    Zhonghua Xue Ye Xue Za Zhi; 2022 Apr; 43(4):287-292. PubMed ID: 35680626
    [No Abstract]   [Full Text] [Related]  

  • 45. Intensive chemotherapy and reduced-intensity allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia in elderly patients.
    Jackson K; Kennedy G; Mollee P; Marlton P; Morris K
    Asia Pac J Clin Oncol; 2014 Sep; 10(3):246-54. PubMed ID: 24673966
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The Superiority of Allogeneic Hematopoietic Stem Cell Transplantation Over Chemotherapy Alone in the Treatment of Acute Myeloid Leukemia Patients with Mixed Lineage Leukemia (MLL) Rearrangements.
    Yang H; Huang S; Zhu CY; Gao L; Zhu HY; Lv N; Jing Y; Yu L
    Med Sci Monit; 2016 Jul; 22():2315-23. PubMed ID: 27373985
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial.
    Heuser M; Smith BD; Fiedler W; Sekeres MA; Montesinos P; Leber B; Merchant A; Papayannidis C; Pérez-Simón JA; Hoang CJ; O'Brien T; Ma WW; Zeremski M; O'Connell A; Chan G; Cortes JE
    Ann Hematol; 2021 May; 100(5):1181-1194. PubMed ID: 33740113
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Upfront allogeneic hematopoietic cell transplantation (HCT) versus remission induction chemotherapy followed by allogeneic HCT for acute myeloid leukemia with multilineage dysplasia: A propensity score matched analysis.
    Konuma T; Harada K; Yamasaki S; Mizuno S; Uchida N; Takahashi S; Onizuka M; Nakamae H; Hidaka M; Fukuda T; Ohashi K; Kohno A; Matsushita A; Kanamori H; Ashida T; Kanda J; Atsuta Y; Yano S;
    Am J Hematol; 2019 Jan; 94(1):103-110. PubMed ID: 30370944
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Risk Stratification and Prognosticators of Acute Myeloid Leukemia with Myelodysplasia-Related Changes in Patients Undergoing Allogeneic Stem Cell Transplantation: A Retrospective Study of the Adult Acute Myeloid Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation.
    Harada K; Konuma T; Machida S; Mori J; Aoki J; Uchida N; Ohashi K; Fukuda T; Tanaka M; Ikegame K; Ozawa Y; Iwato K; Eto T; Onizuka M; Ichinohe T; Atsuta Y; Yano S
    Biol Blood Marrow Transplant; 2019 Sep; 25(9):1730-1743. PubMed ID: 31054982
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Minimal residual disease by either flow cytometry or cytogenetics prior to an allogeneic hematopoietic stem cell transplant is associated with poor outcome in acute myeloid leukemia.
    Norkin M; Katragadda L; Zou F; Xiong S; Chang M; Dai Y; Hsu JW; Moreb JS; Leather H; Murthy HS; Farhadfar N; Li Y; Hromas R; Brown RA; Cogle CR; Wingard JR
    Blood Cancer J; 2017 Nov; 7(12):634. PubMed ID: 29176662
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Quality of Life following Allogeneic Stem Cell Transplantation for Patients Age >60 Years with Acute Myelogenous Leukemia.
    Wright R; Oremek M; Davies D; Kewley C; Singh A; Taitt N; Kempshall E; Wilson K; Ingram W
    Biol Blood Marrow Transplant; 2020 Aug; 26(8):1527-1533. PubMed ID: 32422252
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Low WT1 transcript levels at diagnosis predicted poor outcomes of acute myeloid leukemia patients with t(8;21) who received chemotherapy or allogeneic hematopoietic stem cell transplantation.
    Qin YZ; Wang Y; Zhu HH; Gale RP; Zhang MJ; Jiang Q; Jiang H; Xu LP; Chen H; Zhang XH; Liu YR; Lai YY; Jiang B; Liu KY; Huang XJ
    Chin J Cancer; 2016 May; 35():46. PubMed ID: 27197573
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Reduced-intensity conditioning with fludarabine and busulfan versus fludarabine and melphalan for patients with acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
    Baron F; Labopin M; Peniket A; Jindra P; Afanasyev B; Sanz MA; Deconinck E; Nagler A; Mohty M
    Cancer; 2015 Apr; 121(7):1048-55. PubMed ID: 25424330
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Allogeneic hematopoietic stem cell transplantation for treatment of refractory and relapsed acute myeloid leukemia: outcomes and prognostic factors].
    Su XH; Yao JF; Zhang GX; He Y; Wei JL; Ma QL; Yang DL; Huang Y; Zhai WH; Liang C; Li G; Chen X; Feng SZ; Han MZ; Jiang EL
    Zhonghua Xue Ye Xue Za Zhi; 2017 Dec; 38(12):1024-1030. PubMed ID: 29365394
    [No Abstract]   [Full Text] [Related]  

  • 55. A Markov decision analysis of allogeneic hematopoietic cell transplantation versus chemotherapy in patients with acute myeloid leukemia in first remission.
    Kurosawa S; Yamaguchi T; Miyawaki S; Uchida N; Kanamori H; Usuki K; Yamashita T; Watanabe M; Yakushiji K; Yano S; Nawa Y; Taguchi J; Takeuchi J; Tomiyama J; Nakamura Y; Miura I; Kanda Y; Takaue Y; Fukuda T
    Blood; 2011 Feb; 117(7):2113-20. PubMed ID: 21106987
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Impact of induction chemotherapy with intermediate-dosed cytarabine and subsequent allogeneic stem cell transplantation on the outcome of high-risk acute myeloid leukemia.
    Fleischmann M; Schnetzke U; Frietsch JJ; Sayer HG; Schrenk K; Hammersen J; Glaser A; Hilgendorf I; Hochhaus A; Scholl S
    J Cancer Res Clin Oncol; 2022 Jun; 148(6):1481-1492. PubMed ID: 34297206
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Not type of induction therapy but consolidation with allogeneic hematopoietic cell transplantation determines outcome in older AML patients: A single center experience of 355 consecutive patients.
    Hilberink J; Hazenberg C; van den Berg E; Mulder A; Schuringa JJ; van der Helm L; de Groot M; Choi G; de Bock GH; Vellenga E; Ammatuna E; Huls G
    Leuk Res; 2019 May; 80():33-39. PubMed ID: 30954622
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Association of Second Allogeneic Hematopoietic Cell Transplant vs Donor Lymphocyte Infusion With Overall Survival in Patients With Acute Myeloid Leukemia Relapse.
    Kharfan-Dabaja MA; Labopin M; Polge E; Nishihori T; Bazarbachi A; Finke J; Stadler M; Ehninger G; Lioure B; Schaap N; Afanasyev B; Yeshurun M; Isaksson C; Maertens J; Chalandon Y; Schmid C; Nagler A; Mohty M
    JAMA Oncol; 2018 Sep; 4(9):1245-1253. PubMed ID: 30003233
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Outcome and late effects among acute myeloid leukemia survivors: a nationwide population-based study.
    Chang KH; Hwang WL; Muo CH; Hsu CY; Teng CJ
    Support Care Cancer; 2016 Dec; 24(12):4993-5000. PubMed ID: 27502072
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Impact of a novel prognostic model, hematopoietic cell transplant-composite risk (HCT-CR), on allogeneic transplant outcomes in patients with acute myeloid leukemia and myelodysplastic syndrome.
    Kongtim P; Parmar S; Milton DR; Perez JMR; Rondon G; Chen J; Chilkulwar AR; Al-Atrash G; Alousi A; Andersson BS; Im JS; Hosing CM; Bashir Q; Khouri I; Kebriaei P; Oran B; Popat U; Champlin R; Ciurea SO
    Bone Marrow Transplant; 2019 Jun; 54(6):839-848. PubMed ID: 30258129
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.